PDS Biotechnology CEO granted 548,782 stock options

PDS Biotechnology Corp reported that President and CEO Frank Bedu-Addo received a grant of stock options covering 548,782 shares of the company’s stock.

Rhea-AI Filing Summary

PDS Biotechnology Corp reported that President and CEO Frank Bedu-Addo received a grant of stock options covering 548,782 shares of the company’s stock. The options were granted at an exercise price of $0.00 per share as an employee stock option award.

According to the terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on his continued service with the company through each vesting date.

Insider Trade Summary

Grant/Award: 548,782 shares

Grant/Award 1 txn

Insider BEDU-ADDO FRANK

Role President/CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	548,782	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 548,782 contracts (Direct)

Footnotes (1)

1. F1. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PDSB report for Frank Bedu-Addo?

PDS Biotechnology reported that President and CEO Frank Bedu-Addo received a grant of stock options for 548,782 shares. The filing describes this as an employee stock option award with no stated exercise price per share in the reported transaction data.

How many stock options were granted to the PDSB CEO in this Form 4?

The Form 4 shows a grant of employee stock options covering 548,782 shares to PDS Biotechnology’s CEO. All 548,782 options are reported as directly owned following the transaction, reflecting a single grant/award acquisition transaction under the company’s equity compensation arrangements.

What is the vesting schedule for Frank Bedu-Addo’s PDSB option grant?

The option vests over four years. Twenty-five percent of the shares vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, conditioned on his continued service with PDS Biotechnology through each vesting date.

Is the PDSB CEO’s option grant reported as a purchase or an award?

The transaction is reported as a grant or award, not an open-market purchase. The Form 4 classifies it under code "A" as a grant, award, or other acquisition of derivative securities, specifically an employee stock option with direct ownership by the reporting person.

What does the transaction code "A" mean in the PDSB Form 4 filing?

In this filing, code "A" indicates a grant, award, or other acquisition of derivative securities. It is used to describe the CEO’s employee stock option grant for 548,782 shares, rather than a market buy or sell transaction in PDS Biotechnology common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BEDU-ADDO FRANK

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President/CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.98	01/12/2026		A		548,782		(1)	01/12/2036	Common Stock	548,782	$0	548,782	D

Explanation of Responses:

1. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Spencer Brown, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.